Feasibility · Breast cancer · Phase II–III
Breast cancer trial feasibility, cited to its source.
Breast-cancer feasibility hinges on receptor subtype (HR+/HER2+/triple-negative) and line of therapy. Each subtype behaves like a distinct indication for site selection and enrollment, so a single "breast cancer" estimate is rarely defensible.
Deterministic, re-runnable feasibility scoring.
What drives feasibility here
The questions that decide go or no-go.
- Receptor subtype defines the real addressable cohort and the relevant competitor set.
- Triple-negative populations are smaller and more contested, raising reachability risk.
- Adjuvant vs metastatic settings have very different site and screening dynamics.
- Rich approval history gives strong precedent priors for PTRS.
Grounded in public data
For breast cancer, the verdict draws primarily on ClinicalTrials.gov, AACT, PubMed, FDA, Open Targets — every figure links back to its source record with a snapshot date, so your team and the sponsor can re-verify it. See the full data sources and compare other indications.
See a cited verdict for breast cancer.
Send us a protocol. We'll return a fully cited feasibility verdict you can trace, line by line, back to public data — yours to white-label, defend in a bid, or hand to a regulator.